COVID-19 Records

FYI OMB Meeting

Reading Room Production, p.446 · reading_room:email:00440

Page text: p.446 · original PDF

Date
2010-01-27 10:12
Type
email · email
to
Anthony S. Fauci
Topics
Intelligence community assessmentsVaccines
This is on for Friday from 1-2 pm downtown- will you need any prep? Interesting...Nicki is not one of the attendees "thus far"!! The attendees of the meeting thus far are: Merck I, Novartis I, NKT Therapeutics , Hecker and Associates Tony Fauci, NIAID GSK Heidi Avery, NSC Richard Hatchett, NSC Zeke Emanuel, OMB A brief agenda from Zeke is: 1) Introductions 2) Introduction of new initiative 3) Discussion of specific changes in Govt policy to facilitate drug and vaccine development a) Regulations b) Research support c) Manufacturing Patricia L. Conrad Public Health Analyst and Special Assistant to the Director National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda, MD 20892-2520 Phon Fax! The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

In context

A single line often inverts meaning once you see what it answers, so neighbouring messages are always shown.

  1. 2010-01-27 10:12 unattributed
    This is on for Friday from 1-2 pm downtown- will you need any prep? Interesting...Nicki is not one of the attendees "thus far"!! The attendees of the meeting thus far are: Merck I, Novartis I, NKT Therapeutics , Hecker and Associates Tony Fauci, NIAID GSK Heidi Avery, NSC Richard Hatchett, NSC Zeke Emanuel, OMB A brief agenda from Zeke is: 1) Introductions 2) Introduction of new initiative 3) Discussion of specific changes in Govt policy to facilitate drug and vaccine development a) Regulations b) Research support c) Manufacturing Patricia L. Conrad Public Health Analyst and Special Assistant to the Director National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda, MD 20892-2520 Phon Fax! The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Full conversation →